TREM2 and neoplasm: We previously demonstrated that anti-TREM2 reshaped tumor-associated macrophages, reducing CX3CR1+CD206+ macrophages while concomitantly expanding macrophages expressing immunostimulatory molecules.77 We hypothesized that targeting the CX3CR1+CD206+ macrophages in our vaccine setting could extend the therapeutic window for neoAg SLP vaccines.